Biogen Idec Inc. (BIIB) is seeing some unnecessary weakness Wednesday following Q3 results and the company's conference call.Earlier, the WSJ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Conference Calls FDA Management Comments Trader Talk

RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform RatingOctober 22, 2014 1:27 PM Baird Upgrades Biogen (BIIB) to OutperformOctober 22, 2014 12:45 PM Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)October 22, 2014 10:52 AM Form 8-K BIOGEN IDEC INC. For: Oct 22October 22, 2014 7:23 AM Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS OutlookOctober 22, 2014 7:06 AM